Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 07:01 ET | Source: Agios Pharmaceuticals

Agios Reports Second Quarter 2016 Financial Results

- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by...
July 28, 2016 16:01 ET | Source: Agios Pharmaceuticals

Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016

CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
June 11, 2016 08:00 ET | Source: Agios Pharmaceuticals

AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency

- 9 of 18 Total Patients and 9 of 13 Patients with at Least One Missense Mutation Showed Maximal Hemoglobin Increases Between 2.3 to 4.9 g/dL - - AG-348 Well Tolerated with...
June 09, 2016 09:21 ET | Source: Agios Pharmaceuticals

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers

- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation...
June 01, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Host Conference Call from the 21st Congress of the European Hematology Association

CAMBRIDGE, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that...
May 19, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association

Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Company to Host Conference Call and Webcast on Saturday, June 11,...
May 17, 2016 16:02 ET | Source: Agios Pharmaceuticals, Inc.

Agios Updates 2016 Financial Guidance

- $200 Million Upfront Payment from Celgene for New Metabolic Immuno-Oncology Collaboration - - Agios Expects 2016 Ending Cash Position of More than $390 Million - - Investor Conference Call...
May 17, 2016 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement

- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment - - AG-120 Rights Outside the United States Transferred to...
May 05, 2016 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2016 Financial Results

Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Enrollment Complete...
May 02, 2016 08:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016

CAMBRIDGE, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that...